Furthermore, it has been demonstrated that MLL-positive BCP-ALL displays a hypermethylated CpG promotor pattern providing a rationale for the evaluation of HMA approaches [10]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.